Avillion announces positive high-level results from Phase III BATURA trial with AstraZeneca's inhaled anti-inflammatory medication Airsupra in asthma patients

Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysisPhase IIIb clinical development of Airsupra was conducted by Avillion under an exclusive clinical co-development agreement with AstraZeneca Airsupra (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in risk of severe asthma exacerbations in patients with intermittent or mild persistent asthma compared to albuterol alone London, UK, 7 October ...